SCHEMBL7538429

SCHEMBL7538429

Cc1ccc(NS(=O)(=O)c2cc3c(cc2C)oc(=O)n3C)cc1C

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 14/20 0.71
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
TP53 P04637 3/20 0.50
HTT P42858 2/20 0.50
MAPK1 P28482 1/20 0.50
GAA P10253 1/20 0.50
GFER P55789 1/20 0.50
TAS2R14 Q9NYV8 1/20 0.50
LMNA P02545 2/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
GLA P06280 1/20 0.48
MAPT P10636 1/20 0.48
RAB9A P51151 1/20 0.48
HPGD P15428 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7534803 0.90 PKM (0.57) PKMMEN1KMT2ATP53HTT
SCHEMBL7538485 0.90 PKM (0.72) PKMMEN1KMT2ATP53HTT
SCHEMBL7538701 0.87 PKM (0.55) PKMMEN1KMT2ATP53HTT
SCHEMBL7537618 0.87 PKM (0.68) PKMMEN1KMT2ATP53HTT
SCHEMBL7541848 0.87 PKM (0.67) PKMMEN1KMT2ATP53HTT
SCHEMBL7537874 0.85 PKM (0.51) PKMMEN1KMT2ATP53HTT
SCHEMBL7539651 0.84 PKM (0.57) PKMMEN1KMT2ATP53TAS2R14
SCHEMBL7541452 0.84 PKM (0.70) PKMMEN1KMT2ATP53HTT
SCHEMBL7537494 0.84 PKM (0.60) PKMMEN1KMT2ATP53HTT
SCHEMBL7539740 0.84 TP53 (0.54) PKMMEN1KMT2ATP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS INC (US) 2017-01-12 US disclosed
EP-2427441-B1 PKM2 ACTIVATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS INC (US) 2016-12-14 EP disclosed
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE AGIOS PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8501953-B2 PKM2 modulators for use in the treatment of cancer AGIOS PHARMACEUTICALS, INC (US) 2013-08-06 US disclosed
WO-2013056153-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE KUNG CHARLES (US) 2013-04-18 WO disclosed
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. 2012-05-17 US disclosed
WO-2010129596-A1 PMK2 MODULATORS FOR USE IN THE TREATMENT OF CANCER AGIOS PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122849-A1 PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER PDK2, PDK1, PDK3 PKM 5/4885MEN1 3231/4885KMT2A 429/4885
US-20140249150-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 PKM 11/4885MEN1 4239/4885KMT2A 848/4885
US-20170007608-A1 ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE PDK1, PC, PDK2 PKM 11/4885MEN1 4239/4885KMT2A 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.